胰臟癌治療新趨勢

10.6666/ClinMed.202008_86(2).0091

李君陽；李重賓

胰臟腺癌（pancreatic adenocarcinoma） ； 化學治療（chemotherapy） ； 存活（survival）

臨床醫學月刊

86卷2期（2020 / 08 / 28）

505 - 508

繁體中文

胰臟癌的早期診斷較為困難，且胰臟鄰近大血管與其他重要器官，因此增加了手術切除的困難性。以現階段醫學而言，胰臟癌的治療雖有進步但治療預後仍比其他種類的癌症差，縱使有許多新興的癌症治療於近幾年浮現，手術、化學藥物與標靶藥物治療依然是胰臟癌病患的主要選擇。

1. American Cancer Society(2016).Cancer Facts & Figures 2016.Atlanta, GA:American Cancer Society.
2. Bilimoria, KY,Bentrem, DJ,Ko, CY(2007).National failure to operate on early stage pancreatic cancer.Ann Surg,246,173-180.
3. Burris, HA, 3rd,Moore, MJ,Andersen, J(1997).Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients ith advanced pancreas cancer: a randomized trial.J Clin Oncol,15,2403-2413.
4. Conroy, T,Desseigne, F,Ychou, M(2011).FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J ed,364,1817-1825.
5. Gill, S,Ko, YJ,Cripps, C(2016).PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy.J Clin Oncol,34,3914-3920.
6. Modolell, I,Guarner, L,Malagelada, JR(1999).Vagaries of clinical presentation of pancreatic and biliary tract cancer.Ann Oncol,10,82-84.
7. Moore, Malcolm J,Goldstein, David(2007).Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,25,1960-1966.
8. Pelzer, U,Schwaner, I,Stieler, J(2011).Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III study from the German CONKO-study group.Eur J Cancer,47,1676-1681.
9. Talia, Golan,Pascal, Hammel(2019).Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic.Cancer N Engl J Med,381,317-327.
10. Tobita, K,Kijima, H,Dowaki, S(2003).Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis.Int J Mol Med,11,305-309.
11. Von Hoff, DD,Ervin, T,Arena, FP(2013).Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med,369,1691-1703.
12. Wang-Gillam, A,Li, CP,Bodoky, G(2016).Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1).Lancet,387,545-557.
13. Zhang, KJ,Dyson, G,Gatz, JL(2019).Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs：10-Year Experience of a Single NCI-designated Comprehensive Cancer Center.Am J Clin Oncol,42,243-246.
14. 衛生福利部106年死因統計結果分析，圖7-十大癌症死因死亡率-106年 vs. 96年。

1. 范文燁(2021)。一位胰臟癌末期個案之護理經驗。新臺北護理期刊，23(2)，166-174。
2. (2024)。一位初診斷胰臟癌末期患者之照護經驗。領導護理，25(2)，113-127。